Lisa Bronaugh, NP
Family · Easton, MDNPI 1932651700
Payments from drug & device makers
Across 186 payments — averaging $23.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$875
- Novo Nordisk$788
- Sanofi-aventis U.S. LLC$576
- Tandem Diabetes Care, Inc.$290
- Abbott$247
- Dexcom, Inc.$203
- plus $1K from 18 others
What the payments were for
- Food & beverage$4,345100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 40 | $875 |
| Novo Nordisk | 41 | $788 |
| Sanofi-aventis U.S. LLC | 18 | $576 |
| Tandem Diabetes Care, Inc. | 7 | $290 |
| Abbott | 13 | $247 |
| Dexcom, Inc. | 8 | $203 |
| Insulet Corporation | 7 | $159 |
| Amneal Pharmaceuticals LLC | 8 | $153 |
| AstraZeneca(2 entities) | 8 | $152 |
| Medtronic | 3 | $139 |
| Cequr Corporation | 4 | $135 |
| Xeris Pharmaceuticals, Inc. | 6 | $119 |
| Corcept Therapeutics | 5 | $114 |
| Sequel Med Tech, LLC | 2 | $103 |
| Boehringer Ingelheim | 4 | $83 |
| Bayer | 4 | $65 |
| Radius Health, Inc. | 1 | $28 |
| Recordati_rare_diseases_inc. | 1 | $22 |
| Amryt Pharma Holdings Ltd | 1 | $22 |
| Averitas Pharma Inc. | 1 | $21 |
| Merck | 1 | $20 |
| Ipsen Biopharmaceuticals, Inc | 1 | $18 |
| Lifescan, Inc. | 1 | $14 |
| Zealand Pharma US, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$111
How this compares
$4,356 in reported general payments places this provider in the 90th percentile of 2,843 family providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 454 | $519,533 |
| MounjaroTirzepatide | 194 | $289,156 |
| JardianceEmpagliflozin | 266 | $223,723 |
| TrulicityDulaglutide | 105 | $121,497 |
| FarxigaDapagliflozin Propanediol | 114 | $104,079 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 107 | $86,431 |
| RybelsusSemaglutide | 59 | $80,211 |
| Tresiba Flextouch U-200Insulin Degludec | 77 | $76,494 |
| JanuviaSitagliptin Phosphate | 71 | $67,555 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 80 | $66,988 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 76 | $59,403 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 40 | $54,879 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 118 | $50,029 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 59 | $45,508 |
| Tresiba Flextouch U-100Insulin Degludec | 79 | $42,907 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog Mix 70-30 | $788 | $602,158525 claims |
| Lilly USA, LLCMounjaro, Trulicity | $875 | $410,653299 claims |
| Boehringer IngelheimJardiance, Tradjenta | $83 | $241,070289 claims |
| AstraZenecaFarxiga | $152 | $104,079114 claims |
| MerckJanuvia | $20 | $67,55571 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $576 | $66,98880 claims |
| BayerKerendia | $65 | $7,62712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,843 family providers in Maryland.
Other family in Easton
- Ariana ChaoLutherville$727K
- Erika HoffmanPotomac$226K
- Caroline MansySalisbury$106K
- Hazel Jones-ParkerBaltimore$96K
- Brittany WilsonBaltimore$88K
- Meredith SagalHunt Valley$82K
- Sharon Dudley-BrownBel Air$67K
- Joy MaulikSalisbury$47K
- Kristin AttiogbeChevy Chase$42K
- Sametta SanyaoluFulton$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.